Select Page ::

The Infinite composites and AGM and have combined to develop the material for the space exploration – Industry Reporter

Posted on October 13, 2019 by Danzig

Graphene materials maker Applied Graphene Materials (AGM) and weight vessel producer Infinite Composites Technologies have teamed up to build up a composite material for space investigation.Preceding this headway, AGM and Infinite Composites directed an across the board item improvement and testing program.The association saw the utilization of AGMs graphene innovation in two gum frameworks for cryogenic weight tanks.These vessels are as of now being investigated by NASA for use in a few spaceflight missions, just as International Space Station Experiments (MISSE), Artemis and Lunar Gateway programs.The consolidation of AGMs graphene innovation has helped the compartments in finishing their first fluid oxygen stacking test at - 300F.The utilization of AGM innovation brought about the expulsion of almost all microfractures in tar tests.Checking electron magnifying instrument procedures were utilized to perform point by point assessments of the composite structure.Applied Graphene Materials CEO Adrian Potts stated: "AGM is pleased to work with the Infinite Composites group on this energizing improvement exertion to help the eventual fate of room flight and practical transportation."In requesting applications, for example, this, where disappointment isnt an alternative, it is satisfying that our graphene scatterings are driving the exhibition of composite materials. We compliment the Infinite Composites group and anticipate adding to encourage triumphs."In July, Infinite Composites won Oklahomas Small Business Innovative Research award contract from NASA.Under the Nasa MISSE program, the proposition will test Infinite Composites materials for cryogenic tanks outside the ISS.

Here is the original post:

The Infinite composites and AGM and have combined to develop the material for the space exploration - Industry Reporter

Virgin Orbit Is Planning An Ambitious Mission To Mars In 2022 – Forbes

Posted on October 13, 2019 by Danzig

NASA's MarCO spacecraft became the smallest satellites to reach Mars last year.

Richard Bransons Virgin Orbit, a sister company to the space tourism-focused Virgin Galactic, has announced today it intends to launch an ambitious mission to Marsas soon as three years from now opening a new window into interplanetary Solar System exploration.

In a statement released today, the company said it was working with the Polish company SatRevolution to develop a mission to send the worlds first dedicated commercial small satellite mission to Mars. The mission would launch on LauncherOne, an air-launch rocket being designed by the company to operate from its modified Boeing 747 plane, called Cosmic Girl.

We have already seen the incredible utility of small satellites here in Earth orbit, and were thrilled to start providing dedicated launches to deep space, Virgin Orbits Vice President of Business Development Stephen Eisele said in the statement.

Working with SatRevolution and a handful of Polish universities as part of a Mars consortium, Virgin Orbit said it would be designing three scientific missions to travel to Mars, with the first launch expected no sooner than 2022.

Details on the missions havent been revealed yet, but the company noted that spacecraft as small as 50 kilograms would be used to image Mars and its moon Phobos, analyze the Martian atmosphere, and even look for subsurface water.

California-based Virgin Orbit has yet to launch one of its LauncherOne rockets to orbit, but it hopes to do so for the first time later this year. The company plans to operate from multiple spaceports including the Mojave Air and Space Port in California and the under-development Cornwall Spaceport in the U.K.

With a lifting capability of up to 500 kilograms to orbit per launch, the two-stage LauncherOne vehicle measuring 16 meters long is known as a smallsat launcher, comparable to the Electron rocket operated by Rocket Lab from New Zealand. However, a spokesperson for the company said deep space missions such as this were possible with the addition of a third stage, despite the small size of the rocket.

Using a small third stage it is possible to mount missions to Mars, Venus, and the asteroid belt, the spokesperson noted in an email. We believe this could be used to put something in orbit [around Mars], not just a flyby.

LauncherOne will launch from the company's Cosmic Girl plane.

Its understood that owing to the amount of fuel required to reach Mars, only about 10% of the rockets lifting capability could be taken up by the satellite. That should be enough to launch a small satellite to Mars, however, and such missions are not unprecedented.

In November 2018, NASAs InSight lander touched down on Mars, aided by two small CubeSats that had traveled with the mission called MarCO-A and MarCO-B. These small spacecraft weighing 13.5 kilograms each relayed data from the lander back to Earth, giving mission operators rapid information on the successful landing.

Getting to Mars will be no mean feat, but if Virgin Orbit can successfully place small satellites into orbit around the Red Planet, it would open up a huge swathe of possible missions to companies and universities. Already some researchers are looking at ways such small spacecraft might make the journey to Mars using novel propulsion technologies.

Polish scientists and engineers are ready to develop the first-ever interplanetary scientific CubeSat mission, Grzegorz Zwoliski, the president of SatRevolution, said in the statement. The project will accelerate the development of small satellites and of lightweight space science instrument technology.We want Poland to be the go-to country for small interplanetary spacecraft.

Read the rest here:

Virgin Orbit Is Planning An Ambitious Mission To Mars In 2022 - Forbes

Space pianos and upside-down shoes: innovations for life in space – CBC.ca

Posted on October 13, 2019 by Danzig

Space, animminent frontier? Sands Fish, a scientist and researcher, thinks so.

And so do many others who work with him at the MIT Media Lab's Space Exploration Initiative in Boston.

In the lab, Fish and a team of artists, scientists, engineers and designers work on innovative design projects with the goal of translating life on Earth to life in space.

These projects must take into account factors like zero gravity and the quirks of human interaction, among other things.

It's not all complicated technology, either. Things we take for granted in our everyday lives like furniture, shoesand even our hairstyles would have to be altered in order to live comfortably in the great beyond.

On Monday, Fish spoke with Doug Dirks on The Homestretch.

This interview has been edited for clarity and length.

Q: What's the MITMedia space lab all about and what do you do there?

A: The space exploration initiative at the Media Lab is basically a lab where we think about things that are not typically explored in space.

So you can imagine it takes a lot of safety concern, engineering and science to make what happens in space happen. But we're more concerned with all of the things that aren't typically researched in space. Things like art, design and culture.

Q: You did two test flights in zero gravity. What did you test on those particular flights?

A: [For the]first one, we built a musical instrument that's supposed to be performed in zero gravity, as opposed to on the ground.

If you think about a piano, it wouldn't work in zero gravity because it has counterweights that bring the keys back up once you press them.

We created a musical instrument that tries to capture that poetic motion that you see when things float around in zero gravity.

As the instrument floats around in microgravity, you get some notes that maybe are really low and quiet when it's moving slowly. But if you spin it around, it will spin in front of you without you holding on to it, then you'll get a crescendo and you'll get louder notes and then higher notes.

Q: What about the impact of gravity on things like roots and plants and how they grow?

A: Well, on a planetary surface, it depends on how strong the gravity is. In orbit and in microgravity, it's a little bit more complicated.

A lot of people have seen how water behaves [in space] and basically forms these spheres.

You can't really pour water in microgravity into dirt and expect it to saturate the soil, and so you get things like root rot.

Q: Your research involved interviewing a number of astronauts and one of them talked about hair being an issue. What's that about?

A: I was talking to CadyColeman, who is an astronaut who was up at the International Space Station, and I was asking her how she thought culture was going to evolve once we're living in space in a more long-term basis.

She immediately said that she thought hairstyles were going to change.

When she went up there, she wanted to grow her hair out really long so that it was absolutely clear in photographs that a woman was in space.

But when shebraided her hair to keep it kind of out of her own face and others', she realized the texture of the braid was the same texture as the Velcro that they used to keep everything down up there.

You can imagine what happened. She would get caught on something in the wall.

The simple solution I guess would be for everybody to shave their head, right? But I'm pretty sure that that's not the future of hairstyles.

Q: What about shoes? Will we even need shoes [in space]?

A: [Astronauts] usually wear socks, but they tend to complain about pain on the tops of their feet instead of the bottom.

[It] makes sense intuitively. We're not being pressed down against the floor, so we don't really need that.

If you want to stay in one place in zero gravity, you've got to hook your feet under metal bars or straps.

I designed some sneakers that actually inverted that design and basically put the sole on the top of the sneaker instead of the bottom.

That's something we're prototyping now and we tested out on the last zero gravity flight that we went on.

Q: What about the impact on furniture design?

A: There's no up and down in space. So in space architecture, the walls can be the ceilings, the floors can be the walls.

That fundamentally changes the assumptions that you use when you're designing for something like furniture.

Q: How important do you think all this is, addressing mental wellness in space?

A: It's so important to study design and culture and art and how that evolves in space because none of us really want to just work all day and then go to sleep and then get up and work again.

What are the mundane everyday details that we'll have as comforts in space? I think that we haven't studied that quite as much as we could have because we're more focused on scientific and engineering missions. But that's going to become more and more important as we spend more time in space.

Q: Elon Musk and Jeff Bezos would have us believe that we're all going to be going into space here in the next five to 10 years. What do you think?

A: That sounds a bit aggressive.

I'm suspicious of any one person that thinks they know exactly how the future of space is going to go.

I think I'm more interested in trying to build platforms and kind of democratize access to space so that more people can contribute to that vision.

Fish is in Calgary to share some of these ideas at the sixth annual Camp Festival at MRU, running Oct. 7-8.

The festival brings together renowned designers, artists, inventors and professionals to share ideas with a focus this year on the mental wellness of the creative mind.

Go here to read the rest:

Space pianos and upside-down shoes: innovations for life in space - CBC.ca

Lilly Presents Positive Results for Taltz (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European…

Posted on October 13, 2019 by Danzig

INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of patients treated with Taltz achieved a significant 75 percent improvement from baseline to Week 12 on their Psoriasis Area and Severity Index score (PASI 75) and 81 percent of patients treated with Taltz achieved a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1). Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain. Based on these positive results, Lilly plans to submit for U.S. regulatory approval for pediatric patients with moderate to severe plaque psoriasis.

"Results from our study indicate that Taltz may have the potential to clear skin and reduce itch in pediatric patients with moderate to severe plaque psoriasis," said study investigator Kim Papp, MD, PhD, Probity Medical Research, Inc., Waterloo, Ontario, Canada. "While it is estimated that up to one third of people with psoriasis first develop symptoms during childhood, there are limited medications available for pediatric patients. This study provides encouraging data supporting the potential for Taltz to become another treatment option for this patient population."

The co-primary endpoints of the study were the proportion of patients achieving a significant 75 percent improvement from baseline on their Psoriasis Area and Severity Index score (PASI 75) and a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1) at Week 12. Key secondary endpoints included the proportion of patients achieving PASI 90, sPGA (0) and PASI 100 at Week 12, and at least a four-point improvement in Itch Numeric Rating Scale (Itch NRS 4) among patients with baseline Itch NRS 4 at Week 12, as well as PASI 75 and sPGA 0,1 at Week 4. The proportion of patients achieving 0 or 1 on the Children's Dermatology Life Quality Index (CDLQI, patients 6 to 16 years old) or DLQI (patients 17 years old) at Week 12 was also evaluated.

"We recognize that psoriasis can have a significant impact on children and adolescents, causing challenging symptoms and affecting their self-esteem and ability to connect to peers," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We're pleased to see positive results for Taltz in pediatric patients. These results build on more than five years of safety and efficacy data in adults and support the potential for Taltz in this new population, pending regulatory approvals."

A total of 201 patients aged 6 to <18 years of age with moderate to severe plaque psoriasis were randomized to receive Taltz (20 mg for <25 kg, 40 mg for 25-50 kg or 80 mg for >50 kg through Week 12, with 40 mg, 80 mg or 160 mg starting doses, respectively) or placebo. At 12 weeks, the proportion of patients achieving the co-primary endpoints was superior to placebo with statistically significant difference (P<0.001), including:

Taltz also met all major secondary endpoints in the study (P<0.001).

In this trial, the overall safety profile of Taltz was consistent with previously reported results. The Taltz safety profile has been studied across 15 clinical trials in plaque psoriasis and psoriatic arthritis, with 6,989 patients receiving Taltz, with a total exposure of 16,586 patient-years.1,2,3

INDICATIONS AND USAGE FOR TALTZTaltz is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Taltz is also approved for the treatment of adults with active psoriatic arthritis and active ankylosing spondylitis.

IMPORTANT SAFETY INFORMATION FOR TALTZ

CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONSInfectionsTaltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis and ankylosing spondylitis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

HypersensitivitySerious hypersensitivity reactions, including angioedema and urticaria (each 0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel DiseaseDuring Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz 80 mg Q2W group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis and in the Taltz Q4W group in ankylosing spondylitis trials (Crohn's disease 1.0% [2 patients], ulcerative colitis 0.5% [1 patient]) than in the placebo group (Crohn's disease 0.5% [1 patient], ulcerative colitis 0%). In the ankylosing spondylitis trials, serious events occurred in 1 patient in the Taltz group and 1 patient in the placebo group.

ImmunizationsPrior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONSMost common adverse reactions (1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in patients with psoriatic arthritis and ankylosing spondylitis were consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis.

Please see accompanying Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.

IX HCP ISI 23AUG2019

About TaltzTaltz (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.4 IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines.4

About Moderate to Severe Plaque Psoriasis Psoriasis is a chronic, immune disease that affects the skin.5 It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects approximately 125 million people worldwide, approximately 20 percent of whom have moderate to severe plaque psoriasis.5,6 The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.5 Patients with plaque psoriasis often have other serious health conditions, such as diabetes and heart disease and experience negative impact on their quality of life.5

About the Phase 3 Pediatric Study This study is a Phase 3, multicenter, randomized, double-blinded, placebo controlled study to evaluate safety, tolerability and efficacy of Taltz in patients from 6 to <18 years of age with moderate to severe plaque psoriasis. The co-primary endpoints of the study were the proportion of patients achieving a 75 percent improvement from baseline on their Psoriasis Area and Severity Index score (PASI 75) and a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1) at Week 12. Key secondary endpoints included the proportion of patients achieving PASI 90, sPGA 0 and PASI 100 at Week 12, and at least a four-point improvement in Itch numeric rating scale (Itch NRS 4) among patients with baseline Itch NRS 4 at Week 12, as well as PASI 75 and sPGA 0,1 at Week 4. The proportion of patients achieving 0 or 1 on the Children's Dermatology Life Quality Index (CDLQI, patients 6 to 16 years old) or DLQI (patients 17 years old) at Week 12 was also evaluated.

About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives. At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.

About Eli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. P-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a potential treatment for pediatric patients with moderate to severe plaque psoriasis, and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date, that Taltz will receive additional regulatory approvals, or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertake no duty to update forward-looking statements to reflect events after the date of this release.

1 Data on file. Lilly USA, LLC. TAL20171211A.2 Data on file. Lilly USA, LLC. DOF-IX-US-0019.3 Mease P, Roussou E, Burmester GR, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arth Care Res. 2018 (Epub). doi:10.1002/acr.23738.4 Taltz Prescribing Information, 2019.5 Psoriasis media kit. National Psoriasis Foundation website. https://www.psoriasis.org/sites/default/files/for-media/MediaKit.pdf. Accessed September, 2019.6 Skin conditions by the numbers. American Academy of Dermatology website. https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed September, 2019.

SOURCE Eli Lilly and Company

https://www.lilly.com/

Go here to see the original:

Lilly Presents Positive Results for Taltz (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European...

AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress -…

Posted on October 13, 2019 by Danzig

- Twenty new abstracts underscore AbbVie's commitment to advancing standards of care for people living with serious skin diseases

- Results from the LIMMitless trial evaluating continued safety and efficacy with SKYRIZI (risankizumab) in patients with moderate to severe plaque psoriasis at 2.5 years will be presented

- Safety and efficacy data up to 24 weeks will be presented from risankizumab Phase 2 investigational studies for the treatment of active psoriatic arthritis

- New data from a Phase 2b investigational study evaluating time to treatment response with upadacitinib for patients with atopic dermatitis

NORTH CHICAGO, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI (risankizumab) at 2.5 years in adult patients with moderate to severe plaque psoriasis, as well as additional data on HUMIRA (adalimumab) and the investigational JAK inhibitor upadacitinib, at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, in Madrid.

"Leveraging more than two decades of clinical experience with HUMIRA, AbbVie recently expanded its dermatology portfolio with the approval of SKYRIZI for patients living with moderate to severe plaque psoriasis," said Marek Honczarenko, MD, PhD, vice president, global immunology development, AbbVie. "The new data presented at EADV will advance the knowledge around new and existing treatments for serious skin diseases, like psoriasis, as well as diseases with high levels of unmet need, such as atopic dermatitis and hidradenitis suppurativa."

In addition to sharing new long-term data from the LIMMitless open-label extension study in moderate to severe plaque psoriasis, AbbVie will share results from its ongoing investigational Phase 2 program evaluating risankizumab for the treatment of psoriatic arthritis. Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

In addition, Phase 2b results evaluating time to treatment response with upadacitinib, an oral JAK inhibitor, under investigation for patients with moderate to severe atopic dermatitis will be shared as an oral presentation. Upadacitinib is not approved for atopic dermatitis by any regulatory authority, and its safety and efficacy have not been established in this indication.

Additional presentations include efficacy and safety results further evaluating HUMIRA in hidradenitis suppurativa.

"Chronic skin diseases can have a significant physical and psychosocial impact on patients," said Jean-Marie Meurant, board president of the International Alliance of Dermatology Patient Organizations. "While progress has been made to improve the lives of patients, many still do not have access to the treatment and care they need and deserve. It's critical that the scientific community build upon current research to better understand these diseases and continue to keep the patient experience at the forefront of their efforts."

AbbVie Data at EADV

Risankizumab Abstracts Psoriasis

Psoriatic arthritis

Upadacitinib AbstractsAtopic dermatitis

HUMIRA AbstractsPsoriasis

Hidradenitis suppurativa

Disease State AbstractsHidradenitis suppurativa

About SKYRIZI (risankizumab) in the EU1

SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Important EU Safety Information1

SKYRIZI is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients and in clinically important active infections. SKYRIZI may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, SKYRIZI should be used with caution. Treatment with SKYRIZI should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Prior to initiating treatment with SKYRIZI, patients should be evaluated for tuberculosis (TB) infection. Patients receiving SKYRIZI should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating SKYRIZI in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Story continues

The most frequently reported adverse reactions were upper respiratory infections, which occurred in 13 percent of patients. Commonly (greater than or equal to 1/100 to less than 1/10) reported adverse reactions included tinea infections, headache, pruritus, fatigue and injection site reactions.

This is not a complete summary of all safety information. See the full summary of product characteristics (SmPC) at http://www.ema.europa.eu. Globally, prescribing information varies; refer to the individual country product label for complete information.

About Upadacitinib

Discovered and developed by AbbVie, upadacitinib is an investigational, oral, small molecule JAK inhibitor being studied for moderately to severely active rheumatoid arthritis and other immune-mediated inflammatory diseases.2-15 Phase 3 trials of upadacitinib in psoriatic arthritis, Crohn's disease, atopic dermatitis and ulcerative colitis are ongoing and it is also being investigated to treat ankylosing spondylitis and giant cell arteritis.10-15

About HUMIRA in the EU16

HUMIRA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.

HUMIRA is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.

Important EU Safety Information16

HUMIRA is contraindicated in patients with active tuberculosis or other severe infections such as sepsis, and opportunistic infections and in patients with moderate to severe heart failure (NYHA class III/IV). It is also contraindicated in patients hypersensitive to the active substance or to any of the excipients; serious allergic reactions including anaphylaxis have been reported. The use of HUMIRA increases the risk of developing serious infections, including hepatitis B reactivation, which may, in rare cases, be life-threatening. Rare cases of lymphoma and leukemia have been reported in patients treated with HUMIRA. On rare occasions, a severe type of cancer called hepatosplenic T-cell lymphoma has been observed and often results in death. A risk for the development of malignancies in patients treated with TNF-antagonists cannot be excluded. Rare cases of pancytopenia, aplastic anaemia, demyelinating disease, lupus, lupus-related conditions and Stevens-Johnson syndrome have been reported in patients treated with HUMIRA. The most frequently reported adverse events across all indications included respiratory infections, injection site reactions, headache and musculoskeletal pain.

This is not a complete summary of all safety information. Globally, prescribing information varies; refer to the individual country product label for complete information.

Full summary of product characteristics is available at: http://www.ema.europa.eu

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2018 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

View original content:http://www.prnewswire.com/news-releases/abbvie-announces-new-data-from-its-dermatology-portfolio-and-pipeline-at-the-28th-european-academy-of-dermatology-and-venereology-eadv-congress-300934529.html

See the rest here:

AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress -...

Scots psoriasis sufferer opens up on how skin condition can affect mental health and leave her not wanting to – The Scottish Sun

Posted on October 13, 2019 by Danzig

A SCOTS psoriasis sufferer has told how the condition has impacted her relationship by leaving her not wanting to be "touched, cuddled or kissed".

Jude Duncan, 26, has had the irritating skin condition for six years and says it can affect intimate relationships and dating.

The marketing officer, who is a 'Skinfluencer' on Instagram has been with her boyfriend for two years and says she is lucky that he is very supportive.

But she also has moments where her itchy and flaky skin affects her mental health and leaves her not wanting intimacy.

Psoriasis, which affects around 2 per cent of people in the UK, is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.

Jude, from Gourock, told the Scottish Sun: "Im very lucky to have a supportive partner but I know that if I'm not having a great nights sleep, and tossing and turning, then hes not getting a great nights sleep and that can have an impact on them as well.

"Actually having that communication with a partner is really important but it can be really difficult as well for people to open up.

"I'm in a lucky position where I feel very confident with my psoriasis but also sometimes it has felt like if I'm having a flare up I dont want to be touched, I dont want to cuddled, I dont want to be kissed. So it does have that impact on it.

"I wouldn't say that because Im with someone I havent had those difficulties."

She added: "Its very hard to get your partner to understand what you're going through mentally as well as the physical aspect of it.

"And the fact that they cant do anything to help puts a strain on it, so its just different."

Jude also had a period of time before she was in a relationship where she was trying to date - but potential suitors were put off by her condition.

She has hit out at the 'Insta perfect' world which means people can be very shallow and focus on a person's perceived flaws.

She said: "On every date I would be asked 'what's wrong with your face' and stuff like that, so it was definitely a topic of conversation.

"It was the elephant in the room, like when is this going to be brought up.' And thats not how it should be.

"It shouldnt matter if I have a bit of psoriasis on my face or not whether you want a second date, but it really did impact that a lot.

"We live in this Insta perfect world where people with flaws or differences arent seen to be good enough and people dont want to be seen with someone like that.

"But to be honest with you if you have a problem with how I look, I dont really want to date anyone that treats people like that anyway."

Negative affect on Mental Health

Speaking on Mental Health day, Jude explained how various factors surrounding the condition can affect a person's mental wellness.

That includes the discomfort itself, but also the negative impact of how other people treat you.

Stats show that 67 per cent of sufferers believe that the condition can have an affect on your mental health.

Jude said: "If you are uncomfortable and thats causing you to not sleep then thats going to have an affect on your mental health, but also just that uncomfortableness all the time, being in a constant state of irritation, not being able to relax - that is going to have a toll on your mental health.

"A lot of people are like oh lets focus on treating the skin but they dont look at surrounding factors such as mental health.

"Because its such a visual condition it can make you incredibly insecure and really lonely and isolated because it's not really talked about. So that can also have an impact on your mental health because you feel like youre bottling it up and not talking about it.

"If youre not getting any sleep that means the next day you're not going to be functioning to your full potential, and you're stressing yourself out because you're not maybe getting as much done as you want and that's going to result in you stressing out more, which is going to affect your sleep, which is going to affect your mental health and its just a really vicious cycle.

Mental health stats:

Sleep stat:

Relationships stat:

Public perception stat:

Call to action

Latest

STREET DRAMA Watch as police lock down Maryhill Street for 'siege' at Glasgow flat

Exclusive

BRAWL BRUTE Chef battered with baseball bat by Motherwell ace furious at Scotland call-up

NASTY WEATHER Judith Ralston drops F-bomb as she fluffs weather report on BBC Scotland news

Exclusive

JAIL REVENGE Gang rival of Steven 'Bonzo' Daniel held down and repeatedly stabbed in head

Graphic warning

DOG FIGHT SICKO Ayr brute bought cats on Gumtree to use as bait for dogs to rip apart

LOSE CRUISE Angry cruise passengers stage mutiny after their tour swaps Norway for GREENOCK

"I think for me as well, when people stare or make comments, sometimes they mean well but that can really also play on your mental health."

She added: "I definitely had comments in the past. I've had people say really horrible things to my face.

"But I'm OK that in that I'm in a position where I'm confident enough. There's so many people out there that arent and a situation like that would knock their confidence.

"I was in a position that I was able to move on and deal with it but thats not always the case."

If you are affected by any of the issues raised in this article, please call the Samaritans on (free) 116123.

We pay for your stories and videos! Do you have a story or video for The Scottish Sun? Email us at scoop@thesun.co.uk or call 0141 420 5300

Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology…

Posted on October 13, 2019 by Danzig

Research from Taltz, Olumiant and mirikizumab highlight the impact Lilly's medicines may have for patients around the world

INDIANAPOLIS, Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data for Taltz (ixekizumab), Olumiant (baricitinib) and mirikizumab at the 28th annual European Academy of Dermatology and Venereology (EADV) Congress taking place Oct. 9-13 in Madrid, Spain. The research being highlighted at this year's meeting reinforces Lilly's commitment to developing treatments for individuals living with dermatological conditions such as psoriasis, psoriatic arthritis, atopic dermatitis and alopecia areata.

"Lilly is proud to showcase data from our dermatology portfolio at EADV this year. Our scientific expertise in dermatology has helped increase the number of available treatment options for patients around the world living with skin-related diseases," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We aspire to raise expectations as to how these diseases are treated so people can live their lives without compromise."

Lilly will present findings from a Phase 3 trial of Taltz for pediatric patients with moderate to severe psoriasis as a late-breaking oral presentation at this year's meeting. The company also will be sharing results from a patient survey evaluating treatment expectations and burden of disease for patients living with psoriasis.

For baricitinib, Lilly will present a late-breaking presentation of the BREEZE-AD7 clinical trial. BREEZE-AD7 is an investigational study measuring the efficacy and safety of baricitinib in combination with topical corticosteroids for the treatment of moderate to severe atopic dermatitis (AD) in adults. Lilly and Incyte Corporation (NASDAQ: INCY) are partners in the clinical development of baricitinib. Further, Lilly will present data findings from a real-world study assessing how elements of an individual's quality of life (both functional and emotional) may be impacted by AD.

Posters to be shared around Lilly's investigational compound, mirikizumab, include research from a study measuring patient outcomes and health-related elements of quality of life for individuals with moderate to severe psoriasis.

Studies, along with the times and locations for the data sessions, are highlighted below.

Taltz Data

Oral Presentations

Thursday, October 10

Saturday, October 12

Poster Presentations

Baricitinib Data

Oral Presentations

Saturday, October 12

Poster Presentations

Mirikizumab Data

Poster Presentations

INDICATIONS AND USAGE FOR TALTZTaltz is approved for the treatment of adults with adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Taltz is also approved for the treatment of adults with active psoriatic arthritis and active ankylosing spondylitis.

IMPORTANT SAFETY INFORMATION FOR TALTZ

CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS InfectionsTaltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis and ankylosing spondylitis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

ADVERSE REACTIONSMost common adverse reactions (1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea and tinea infections. Overall, the safety profiles observed in patients with psoriatic arthritis and ankylosing spondylitis were consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis.

Please see accompanying Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.

IX HCP ISI 23AUG2019

Indication and Usage for OLUMIANT (baricitinib) tablets (in the United States) for RA patientsOLUMIANT (baricitinib) 2 mg is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Limitation of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

IMPORTANT SAFETY INFORMATION FOR OLUMIANT (baricitinib) TABLETS

WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS

SERIOUS INFECTIONS: Patients treated with Olumiant are at risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt Olumiant until the infection is controlled. Reported infections include:

Carefully consider the risks and benefits of Olumiant prior to initiating therapy in patients with chronic or recurrent infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with Olumiant including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

MALIGNANCIES: Lymphoma and other malignancies have been observed in patients treated with Olumiant.

THROMBOSIS: Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with Olumiant compared to placebo. In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. Patients with symptoms of thrombosis should be promptly evaluated.

WARNINGS AND PRECAUTIONS

SERIOUS INFECTIONS: The most common serious infections reported with Olumiant included pneumonia, herpes zoster and urinary tract infection. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus and BK virus were reported with Olumiant. Some patients have presented with disseminated rather than local disease and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids. Avoid Olumiant in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating Olumiant in patients:

Closely monitor patients for infections during and after Olumiant treatment. Interrupt Olumiant if a patient develops a serious infection, an opportunistic infection, or sepsis. Do not resume Olumiant until the infection is controlled.

Tuberculosis Before initiating Olumiant evaluate and test patients for latent or active infection and treat patients with latent TB with standard antimycobacterial therapy. Olumiant should not be given to patients with active TB. Consider anti-TB therapy prior to initiating Olumiant in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Monitor patients for TB during Olumiant treatment.

Viral Reactivation Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with Olumiant. If a patient develops herpes zoster, interrupt Olumiant treatment until the episode resolves.

The impact of Olumiant on chronic viral hepatitis reactivation is unknown. Screen for viral hepatitis in accordance with clinical guidelines before initiating Olumiant.

MALIGNANCY AND LYMPHOPROLIFERATIVE DISORDERS: Malignancies were observed in Olumiant clinical studies. Consider the risks and benefits of Olumiant prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing Olumiant in patients who develop a malignancy. NMSCs were reported in patients treated with Olumiant. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

THROMBOSIS: Thrombosis, including DVT and PE, has been observed at an increased incidence in Olumiant-treated patients compared to placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies with Olumiant. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. Use Olumiant with caution in patients who may be at increased risk of thrombosis. If clinical features of DVT/PE or arterial thrombosis occur, evaluate patients promptly and treat appropriately.

GASTROINTESTINAL PERFORATIONS: Gastrointestinal perforations have been reported in Olumiant clinical studies, although the role of JAK inhibition in these events is not known. Use Olumiant with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Promptly evaluate patients who present with new onset abdominal symptoms for early identification of gastrointestinal perforation.

LABORATORY ABNORMALITIES: Neutropenia Olumiant treatment was associated with an increased incidence of neutropenia (absolute neutrophil count [ANC] <1000 cells/mm3) compared to placebo. Avoid initiation or interrupt Olumiant treatment in patients with an ANC <1000 cells/mm3. Evaluate at baseline and thereafter according to routine patient management.

Lymphopenia Absolute lymphocyte count (ALC) <500 cells/mm3 were reported in Olumiant clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with Olumiant, but not placebo. Avoid initiation or interrupt Olumiant treatment in patients with an ALC <500 cells/mm3. Evaluate at baseline and thereafter according to routine patient management.

Anemia Decreases in hemoglobin levels to <8 g/dL were reported in Olumiant clinical trials. Avoid initiation or interrupt Olumiant treatment in patients with hemoglobin <8 g/dL. Evaluate at baseline and thereafter according to routine patient management.

Liver Enzyme Elevations Olumiant treatment was associated with increased incidence of liver enzyme elevation compared to placebo. Increases to 5x and 10x upper limit of normal were observed for both ALT and AST in patients in Olumiant clinical trials.

Evaluate at baseline and thereafter according to routine patient management. Promptly investigate the cause of liver enzyme elevation to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt Olumiant until this diagnosis is excluded.

Lipid Elevations Treatment with Olumiant was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. Assess lipid parameters approximately 12 weeks following Olumiant initiation. Manage patients according to clinical guidelines for the management of hyperlipidemia.

VACCINATIONS: Avoid use of live vaccines with Olumiant. Update immunizations in agreement with current immunization guidelines prior to initiating Olumiant therapy.

ADVERSE REACTIONSAdverse reactions (1%) include: upper respiratory tract infections (16.3%, 14.7%, 11.7%), nausea (2.7%, 2.8%, 1.6%), herpes simplex (0.8%, 1.8%, 0.7%) and herpes zoster (1.0%, 1.4%, 0.4%) for Olumiant 2 mg, baricitinib 4 mg, and placebo, respectively.

USE IN SPECIFIC POPULATIONSPREGNANCY AND LACTATION: No information is available to support the use of Olumiant in pregnancy or lactation. Advise women not to breastfeed during treatment with Olumiant.

HEPATIC AND RENAL IMPAIRMENT: Olumiant is not recommended in patients with severe hepatic impairment or in patients with moderate or severe renal impairment.

Please click to access full Prescribing Information, including Boxed Warning about Serious infections, Malignancies, and Thrombosis, and Medication Guide.

BA HCP ISI 01JUN2018

About Taltz Taltz (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.1 IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines.1

About OLUMIANT OLUMIANT is a once-daily, oral JAK inhibitor approved in the U.S. for the treatment of adults with moderately- to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF inhibitor therapies, and approved outside of the U.S. for patients with moderately- to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs.2 There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases.3 OLUMIANT has greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3; however, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.2 OLUMIANT is approved in more than 60 countries.

About Mirikizumab Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune diseases, including psoriasis, ulcerative colitis and Crohn's disease.

About Moderate to Severe Plaque Psoriasis Psoriasis is a chronic, immune disease that affects the skin.4 It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects approximately 125 million people worldwide, approximately 20 percent of whom have moderate to severe plaque psoriasis.4,5 The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.4 Patients with plaque psoriasis often have other serious health conditions, such as diabetes and heart disease and experience negative impact on their quality of life.4

About Atopic DermatitisAtopic dermatitis (AD), a serious form of atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.6 AD is a heterogeneous disease both clinically and biologically, but may be characterized by chronic baseline symptoms of itch, redness and skin damage that are often punctuated with episodic, sometimes unpredictable, flares or exacerbations.7,8 AD affects approximately 1-3 percent of adults worldwide.9

Moderate to severe AD is characterized by intense itching, resulting in visibly damaged skin.10 Like other chronic inflammatory diseases, AD is immune-mediated and involves a complex interplay of immune cells and inflammatory cytokines.11

About BREEZE-AD7The BREEZE-AD7 clinical trial is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study that evaluated the efficacy and safety of baricitinib in combination with topical corticosteroids in adult patients with moderate to severe atopic dermatitis. Two doses were evaluated separately such that the primary objective of the study could be met if one or both doses achieved the primary endpoint. The primary endpoint evaluated significant improvement in disease activity as determined by the proportion of patients on baricitinib achieving clear (0) or almost clear skin (1) with a greater than or equal to 2-point improvement as measured by the validated 5-point Investigator's Global Assessment for AD (vIGA) scale at 16 weeks of treatment. BREEZE-AD7 is the third of five Phase 3 studies that make up the BREEZE-AD program. Lilly previously announced results for BREEZE-AD1 and BREEZE-AD2 earlier this year.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab), OLUMIANT (baricitinib), and mirikizumab, and reflects Lilly's and Incyte's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that mirikizumab will receive regulatory approval, that Taltz or OLUMIANT will receive additional regulatory approvals, or that any will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's and Incyte's most recent respective Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly and Incyte undertake no duty to update forward-looking statements to reflect events after the date of this release.

_______________________________1 Taltz Prescribing Information, 2019.2 Olumiant Prescribing Information, 2018.3 Walker JG and Smith MD. J Rheumatol. 2005;32;1650-1653.4 Psoriasis media kit. National Psoriasis Foundation website. https://www.psoriasis.org/sites/default/files/for-media/MediaKit.pdf. Accessed September, 2019.5 Skin conditions by the numbers. American Academy of Dermatology website. https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed September, 2019.6 Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. The Journal of Allergy and Clinical Immunology. 2006;118: 226-32.7 Thijs JL, Strickland I, Bruijnzeel-Koomen C, et. al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. The Journal of Allergy and Clinical Immunology. 2017.8 Langan SM, Thomas KS, Williams HC. What is meant by "flare" in atopic dermatitis? A systematic review and proposal. Arch Dermatol. 2006;142:1190-1196.9 Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of Nutrition and Metabolism. 2015;66(suppl 1): 8-16.10 Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Current Allergy and Asthma Reports. 2008;8:306-311.11 Weidinger, S, Novak, N. Atopic dermatitis. The Lancet Volume 387. 2016;10023:1109-1122.

View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-to-unveil-new-data-for-the-treatments-of-complex-dermatological-conditions-at-the-28th-annual-european-academy-of-dermatology-and-venereology-eadv-congress-300933466.html

SOURCE Eli Lilly and Company

Company Codes: NASDAQ-NMS:INCY, NYSE:LLY

View post:

Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology...

Public awareness on psoriasis increasing: health expert – pna.gov.ph

Posted on October 13, 2019 by Danzig

PSORIASIS AWARENESS CAMPAIGN. Dr. Victoria P. Guillano, MD, FPDS, president of the Psoriasis Foundation of the Philippines, Inc. (PFPI) speaks with stakeholders and patients during the World Psoriasis Day celebration in Davao City on Wednesday (Oct. 9, 2019). Guillano says the stigma associated with psoriasis remains but notes that public awareness has continued to increase in the past years. (PNA photo by Digna Banzon)

DAVAO CITY -- The stigma associated with psoriasis disease remains but public awareness continues to increase, a health expert said.

in an interview during the World Psoriasis Day celebration on Wednesday here, Dr. Victoria P. Guillano, MD, FPDS, president of the Psoriasis Foundation of the Philippines, Inc. (PFPI), attributed the increase to more patients seeking treatment .

Guillano said that according to psoriasis patients, the public has slowly learned to understand them.

She said psoriasis is a chronic, immune-mediated inflammatory disease that causes physical, emotional and social burdens.

The presence of associated itch and lesions on visible and sensitive body areas in psoriasis patients are closely related to decreased psychosocial well-being and impact on the quality of life,' she said.

Davao City Mayor Sara Z. Duterte, whose message was read during the celebration, encouraged stakeholders to raise awareness and information on the proper treatment of the disease.

Sara commended the organizing committee of the Southern Philippines Medical Center (SPMC) Department of Dermatology for spearheading the awareness campaign and creating a platform where people with psoriasis can share their experiences and have their voices heard.

I hope this celebration be instrumental in giving the people with psoriasis the access of affordable and appropriate treatment, the mayor said.

Meanwhile, Guillano said psoriasis remains incurable but the skin can be cleared--its treatment ranging from PHP17,000 to PHP250,000 depending on the severity of the case.

"Our campaign includes lecture and wellness programs for the patients and the public as well," she said. (PNA)

See original here:

Public awareness on psoriasis increasing: health expert - pna.gov.ph

IL-41 Levels Elevated in Synovium of Patients With Psoriatic Arthritis – Rheumatology Advisor

Posted on October 13, 2019 by Danzig

Interleukin (IL)-41, also known as Meteorin-like, is expressed in the synovial tissue of patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and osteoarthritis (OA), and is present and inducible in the enthesis, according to study results published in Clinical Immunology.

The study included data from patients who were treatment-naive. Researchers extracted synovial fluid and measured IL-41 levels using enzyme-linked immunosorbent assay; results from the synovial fluid had <10% reproducibility error. Cell cultures and receptor analysis by flow cytometry were performed to achieve appropriate samples. Researchers also obtained patient demographics.

Study results indicated that IL-41 was detectable in synovial fluid samples in patients with PsA, RA and OA, although it was significantly higher in PsA and RA compared with OA (median, 7722 pg/mL; P =.0011 and 8325 pg/mL; P =.0003 vs 5044 pg/mL, respectively). Researchers also obtained levels of IL-41 in synovial fluid from patients with gout; it was higher compared with IL-41 in patients with OA, but statistical significance was not achieved.

Researchers investigated the production of IL-41 in healthy enthesis samples and noted that although minimal IL-41 was produced from enthesis mononuclear cells, entheseal stromal cells produced a significant amount of IL-41 in comparison. Synovial fibroblasts also showed similar levels of IL-41 compared with entheseal stromal cells.

In addition, the researchers assessed whether IL-41 could be induced by disease relevant mediators, including tumor necrosis factor (TNF), IL-17A, and IL-17F. Results showed that when used alone, TNF, IL-17A, and IL-17F did not induce an increase in IL-41, but TNF with IL-17A or IL-17F led to a significant increase in IL-41 production. Study investigators observed similar results with synovial fibroblasts.

Overall, IL-41 was significantly elevated in the synovium and was induced from enthesis stromal cells in patients with PsA.

The precise role of IL-41 in PsA immunopathogenesis requires further study, the researchers concluded.

Reference

Bridgewood C, Russell T, Weedon H, et al. The novel cytokine Metrnl/IL-41 is elevated in psoriatic arthritis synovium and inducible from both entheseal and synovial fibroblasts. J Clin Immunol. 2019;208:108253.

Go here to see the original:

IL-41 Levels Elevated in Synovium of Patients With Psoriatic Arthritis - Rheumatology Advisor

Novartis data show Cosentyx treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and wit…

Posted on October 13, 2019 by Danzig

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE

PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.

Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

Read the original post:

Novartis data show Cosentyx treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and wit...

Lord of the Rings TV series: Bearded men, missing teeth and people over 200cm wanted – Stuff.co.nz

Posted on October 13, 2019 by Danzig

Talent agencies are calling on Kiwis with specific looks to apply to be part of Amazon's Lord of the Rings TV series.

It was confirmed in September after months of speculation that the series would be filmed in Auckland and shooting would begin early next year.

Auckland Tourism, Events and Economic Development (ATEED) has yet to reveal exact shooting locations but one is believed to beKumeu Film Studios, north-west of the city.

Talent agencies, such as Talento and BGT, announced on Wednesday evening that they were looking for people to apply to be in the show.

N/A

The Lord of the Rings series will be filmed in Auckland.

READ MORE:* Lord of The Rings TV series: What we know so far * Lord of the Rings TV series: Potential filming locations in Auckland* Amazon's The Lord of The Rings TV series to start filming in Auckland* Amazon teams up with Warner Bros and Tolkien estate to make a Lord of the Rings television series, reports

"We are looking for a mix of people of all ages, genders/other from multi-racial backgrounds with interesting character faces and physicality's [sic]," Talentosaid on Facebook.

This included people with "earthy, weathered, dark skin", missing teeth and "wonderful" noses.

They were also looking for "bearded hairy" biker men and women, and people with lean, tall androgynous looks.

The agencies were also looking for people with "beautiful, fair, fine bones faces" who would be willing to wear shear clothing.

FACEBOOK

Talento posted on Facebook on Wednesday night looking for talent.

Short people between 137cmand 149cm were wanted, as well as people who were very tall - up to 182cm and over 200cm.

Musicians were also sought after.

As well as the above characteristics, BGT said it was also looking for circus performers who can juggle and walk on stilts.

SUPPLIED

Kiwis with unique looks are wanted to take part in the series.

Red heads "of all ages, shapes and sizes" were wanted - as well as people with lots of freckles.

Theshowis set to be the most expensive series ever made, with costs expected to exceed US$1 billion (NZ$1.3b). Itis expected to premiere in 2021.

When it was confirmed it would be filmed in Auckland,showrunnersand executive producersJ.D Payne and Patrick McKay said "as we searched for the location in which we could bring to life the primordial beauty of the Second Age of Middle Earth, we knew we needed to find somewhere majestic, with pristine coasts, forests, and mountains, that also is a home to world-class sets, studios, and highly skilled and experienced craftspeople and other staff".

ANNA LOREN/STUFF

One shooting location is believed to be Kumeu FIlm Studios.

"And we're happy that we are now able to officially confirm New Zealand as our home for our series based on stories fromJ.R.R. Tolkien'sThe Lord of the Rings.

"We are grateful to the people and the government of New Zealand and especially Auckland for supporting us during this pre-production phase."

Ed Sheeran and Prince Harry unite in video for World Mental Health Day – WRAL.com

Posted on October 13, 2019 by Danzig

By Matthew Robinson, CNN

CNN Prince Harry and Ed Sheeran have teamed up in a video to raise awareness for World Mental Health Day -- with a light-hearted jibe at their own plight as Britain's most famous redheads.

In the video, shared on the official Sussex Royal Instagram account, the famous duo discuss the issue of mental health, and urge everyone to "look out for anybody that might be suffering in silence".

Yet despite the serious message, the video starts on a humorous note. When the pair sit down to discuss their collaboration, Prince Harry explains that Sheeran has the right "skill set" to create a song to help fight the problem.

"This for me is a subject and conversation which is just not talked about enough, I think people all over the world are really suffering," Harry says in a serious tone.

It soon becomes clear that wires have been crossed, when Sheeran begins describing a song he has started writing to challenge the stigma faced by redheads.

"People don't understand what it's like for people like us," he says. "With the jokes and snide comments. I just feel like it's time we stood up and said, 'we're not going to take this anymore. We're ginger and we're going to fight'."

"Umm slightly awkward," Prince Harry responds, noting that he had invited the singer to his house to discuss World Mental Health Day. When Harry explains the miscommunication, Sheeran is seen deleting the words "Gingers United" from a presentation on this laptop.

At the start of the video Sheeran is seen ringing Prince Harry's doorbell, which chimes to the tune of God Save The Queen. Harry opens the door and jokes: "It's like looking in the mirror."

The pair conclude the video with a serious message, urging everyone to reach out to those struggling with mental health issues.

"Guys this World Mental Health Day, reach out, make sure your friends, strangers look out for anyone who might be suffering in silence; we're all in this together," Prince Harry says.

A message released by Kensington Palace in connection with the video, added: "Both Prince Harry and Ed Sheeran want to ensure that not just today, but every day, you look after yourself, your friends and those around you.

"There's no need to suffer in silence -- share how you're feeling, ask how someone is doing and listen for the answer. Be willing to ask for help when you need it and know that we are all in this together."

Mental health has become a cornerstone of Prince Harry's philanthropic work and he spearheaded the Heads Together campaign alongside Prince William and The Duchess of Cambridge in 2017.

That initiative brought together a coalition of eight charities in a bid to tackle stigma surrounding mental health issues, raise awareness and improve the provision of services for sufferers.

World Mental Health Day is marked annually on October 10, and the World Federation for Mental Health chose suicide prevention as the main focus for this year's event.

Every year close to 800,000 people die from suicide around the world, according to the World Health Organization. In the UK alone there were 6,507 deaths from suicide in 2018, government data shows.

To mark the day, Prince Harry also visited a school in the British city of Nottingham to talk with students about mental health and the challenges they face in education.

Here is the original post:

Ed Sheeran and Prince Harry unite in video for World Mental Health Day - WRAL.com

Deep south’s only Democratic governor heads into election runoff – The Guardian

Posted on October 13, 2019 by Danzig

Louisiana governor John Bel Edwards told supporters to brace for a barrage of national Republican efforts trying to unseat him, in the five weeks leading to a runoff election.

The deep souths only Democratic governor fell below 50% voter support on Saturday night and was forced into a 16 November run-off against Republican businessman Eddie Rispone.

Donald Trump held an election eve rally urging Louisianas voters to reject Edwards. The president took credit on Twitter for keeping Edwards from a primary victory, and praised Rispone.

The media is not talking about the big Republican victory last night in Louisiana, Trump tweeted on Sunday, where a sitting Democrat Governor was forced into a runoff by not getting 50%. Big upset! Now Eddie Rispone who will be a great Governor, will win!

Edwards told supporters: Weve got a little more work to do. But he said he believes Louisiana voters will embrace the spirit of bipartisanship in November and re-elect him.

Edwards needs cross-party support to win in ruby red Louisiana. He ran on bipartisanship, saying he worked across party lines on all the major initiatives he achieved in his first term in office.

Rispone saw off another Republican, US representative Ralph Abraham, to make the run-off. Trump backed both men.

Deep south's only Democratic governor heads into election runoff - The Guardian

Justin Trudeau Heads North, Fighting for Every Seat in a Tight Race – The New York Times

Posted on October 13, 2019 by Danzig

This is a special Canada Letter for the 2019 Canadian election. Sign up for the newsletter here.

Monday night brought the first official debate of this years campaign, an event largely marked by the six leaders talking over one another. After cycling back home well into the evening from the Canadian Museum of History in Gatineau, Quebec, home of the debates, I was up before dawn the next morning for a very particular election experience.

On Tuesday, the traveling roadshow that is Prime Minister Justin Trudeaus campaign dropped into Iqaluit, the capital of Nunavut, for a few hours. Its probably not a tour experience anyone will soon offer the general public.

As the election enters its final phase, polls suggest that neither Mr. Trudeau nor Andrew Scheer, the Conservative leader, have managed to change voters views in any significant ways, at least when it comes to the popular vote. As they were at the beginning, the two parties and their leaders are deadlocked in a tie.

So this has become an every-seat-counts kind of election. (A reminder for non-Canadian readers: Canadians will not vote for a party or prime minister on Oct. 21. They are electing 338 local members of Parliament.) Nunavut, all 2 million square kilometers of it, is just a single electoral district. The Liberals won it in 2015 and clearly hope to repeat that. Tuesday was Mr. Trudeaus third trip to Nunavut in a year.

Not only is the contingent of reporters who follow Mr. Trudeau and the other leaders around considerably smaller than in the past, its now almost entirely made up of journalists from television networks. Mr. Trudeaus staff told me that reporters and columnists from Canadian newspapers have floated in and out. But a reporter for The Canadian Press news service and I were the only representatives of what event organizers now call print and digital media on the Iqaluit outing.

Like any day on the Liberal campaign, journalists, or more precisely their employers, paid 1,000 Canadian dollars to come along.

Mr. Trudeaus campaign planes have attracted unusual attention this election. First a bus carrying reporters unwisely tried to drive under the wing of one of the planes, damaging it. Then, the Conservatives charged that having two planes undermines Mr. Trudeaus climate change agenda. The Liberals shot back by noting that they buy carbon offsets, while the Conservatives do not.

For reasons no one could explain, we flew to Iqaluit on the Boeing 737-200 usually used by Mr. Trudeaus advance team to move around equipment rather than the one with giant red TRUDEAU banners painted on its sides. I was told by other journalists that the decorated plane is quite nice. As for our aircraft, there are good reasons its called the cargo plane, although its lack of storage space was only matched by an extraordinary lack of leg room.

While several of Mr. Trudeaus aides and his children Ella-Grace and Xavier wandered back to where journalists and the Royal Canadian Mounted Police sat, the prime minister didnt budge from his seat until we landed, three hours after taking off in Ottawa. From an overhead bin, he retrieved a special Nunavut campaign parka, which was overkill given the 5-degree-Celsius temperature.

In 2015, the successful Liberal candidate was Hunter Tootoo who was named fisheries minister by Mr. Trudeau. But an alcohol problem and a messy affair, in which Mr. Tootoo was said to have had relationships with a young female staffer and her mother at the same time, led to his removal from the cabinet and the Liberal caucus.

This time around, the Liberal candidate is Megan Pizzo-Lyall, a former Iqaluit city councilor who is now operations manager for an Inuit investment company. She is facing Leona Aglukkaq, the Conservative who held the district for two terms and had several cabinet posts in Stephen Harpers government.

Mr. Trudeaus agenda included events clearly designed to boost Ms. Pizzo-Lyalls campaign, including a visit to an Inuit seniors center where one woman recalled meeting him as a child when he had accompanied his father, the former Prime Minister Pierre Elliott Trudeau, to the community. Two other women, however, continued with their card game.

But the trip also allowed Mr. Trudeau to use the stunning and thats understating it scenery of Sylvia Grinnell Territorial Park as a backdrop for cameras as he spoke to a national audience about his governments record on the environment and curbing carbon change in particular. The reporters questions? They were mainly focused on the debate.

Along the way, he worked a small crowd that included a grade 10 high school class and received a plastic bag of dried and smoked fish from a woman for the plane ride home.

In an airplane services building at the airport, the reporters and his staff were fed Arctic char panini, something that in an ideal world would be coming to a restaurant near everyone. Three and a half hours after the cargo plane touched down in Iqaluit, it was airborne for Toronto.

Even the vastness of Canadas Arctic, however, provided no relief from the comparative smallness of the countrys political world. At the Toronto airport, Mr. Trudeaus plane had to taxi up next to Mr. Scheers. And as the two red Liberal buses headed out to a suburban hotel, Mr. Scheers big blue buses were pulling in.

On Oct 17, join Ian Austen and Dan Bilefsky for an election-themed phone conversation about where the parties stand and the issues most important to Canadians. Is this close race at a tipping point? RSVP for the call here, and send your questions to nytcanada@nytimes.com.

A native of Windsor, Ontario, Ian Austen was educated in Toronto, lives in Ottawa and has reported about Canada for The New York Times for the past 16 years. Follow him on Twitter at @ianrausten.

Were eager to have your thoughts about this newsletter and events in Canada in general. Please send them to nytcanada@nytimes.com.

Forward it to your friends, and let them know they can sign up here.

See original here:

Justin Trudeau Heads North, Fighting for Every Seat in a Tight Race - The New York Times

Its coming, its coming: Did Washington finally find the keys to unlocking its offensive firepower? – The Seattle Times

Posted on October 13, 2019 by Danzig

TUCSON, Ariz. The crisis was mounting, the frustration was growing, the criticism was multiplying and confusion and ineptitude seemed to be ingrained into Washingtons beleaguered offense.

The Huskies were headed, by all appearances, to another demoralizing defeat against an ostensibly inferior opponent. This was one that would have punctured, once and for all, their hopes of mustering something from a season that once brimmed with optimism. This would have been a stake into the heart.

And then halftime happened, and that narrative was blasted into the Tucson desert, in the wake of a slow-developing but deeply satisfying 51-27 rout of Arizona.

At least for now. The Huskies will head into their vital showdown with Oregon next week believing with evidence to back it up this time that they can indeed be a fully-functioning offense. They feel they unlocked some doors behind which were hidden the keys to shake them out of the offensive malaise which threatened to bury their season.

When you finish a game strong, you carry that over into the next game, said running back Sean McGrew, who exceeded 100 yards for the second time this year and was nearly joined by Salvon Ahmed with 95.

But when the Huskies put on the tape of this game, they will also see a first half that mirrored the multi-faceted breakdowns a week earlier against Stanford. Chris Petersen had been unable to muster much second-half magic in his Washington reign. As was chronicled by Seattle Times columnist Matt Calkins, the Huskies had lost 10 straight games under Petersen in which they were trailing at halftime, and 15 of their last 16.

But this time, he and his staff conjured up some remedies. Or maybe the players just finally were fed up with being stymied by one of the lesser defenses in the Pac-12, knowing that one of the best in the country awaits them next week in the Ducks.

I think we just came together as an offense and realized what we needed to do and just kind of manned up, Ahmed said. It was like, weve got to get this done. Weve got to come out of here with a win.

Sputtering with just 134 yards of total offense in the first half, despite being bestowed with numerous scoring opportunities by their defense, the Huskies unleashed the kind of explosive attack that had been reserved this season mostly for non-conference patsies. After intermission, they put up 316 yards while outscoring Arizona, 38-10.

The instigator on the field was quarterback Jacob Eason, who for a half was heading a passing attack that seemed just as jittery and halting as it had been against Stanford. But in the second half, with a vitally needed new target in freshman Puka Nacua (three catches, 97 yards), Eason went 8-for-10 for 178 yards and two touchdowns.

And the instigator off the field may have been Eason as well. Though Petersen and Ahmed both said that there wasnt much of a fiery message at halftime (There wasnt a lot to be said, but there was a lot to still do, is how Ahmed put it) Eason said he stepped out of his comfort zone to assert a vocal leadership presence. He plans to keep doing that, which might be the most promising development of all to come out of this victory.

The players clearly responded to all of it the 17-13 halftime deficit, the mounting red-zone woes and inability to sustain an offensive rhythm. Ahmed said they challenged themselves to be more physical on offense, and felt their running game eventually wore down the Wildcats. And the Huskies responded in a huge way to Easons challenge that it was time to get it done.

It was a message of, we know what we can do, Eason said. We know the kind of offense we are, we know the guys we have, the skill players, the o-line. We can move people up front, We can make plays on the ball and we can run the ball really well. We just have to be able to believe that.

Like I told Puka, its coming, its coming, its coming. In the fourth quarter, he had that go-ball conversion. Guys have to believe in themselves. When the guys believe in themselves, were a dangerous team. That showed in the second half.

This was a game that the Huskies should have seized control of almost immediately, wringing the spirit out of Arizona before it was allowed to be restored. But in the first half, it was the Huskies who were rendered confused and on the verge of demoralization.

The Husky defense, chided last week for being out-physicaled by Stanford, came out with a vengeance, augmented by a ferocious special teams unit. The combo produced a blocked punt, a scoop-and-score touchdown, and a fumble recovery at the Arizona 8 on a muffed punt.

Yet the Husky offense did not reward that largesse in the slightest in the first half, succumbing to the same old maladies. Inept red-zone performance. Head-scratching play calling. A passing game that seemed lost at sea, and a rushing attack that couldnt get the tough yards near the end zone.

Just a really slow start on offense, but our defense was spectacular, really, that first quarter and a half, Petersen said. We just couldnt get any rhythm going on offense. We had these unbelievable field positions, and then three and out, field goal, whatever. So the whole first half was very, very frustrating on offense.

And then that frustration morphed into the exhilaration of their second-half surge. Asked if it was something the Huskies could sustain and carry forward to next week, Petersen let out a big sigh and gave a wan smile.

I sure hope so, right? I think the thing thats as frustrating as anything is being in the red zone, having that unbelievable field position, and just not getting anything done there.

We have to spend more time in practice in that area. We just have to. We have to allow more time to it, and your time is so tight with these different situations. But we just have to spend more time there.

Just maybe, on Saturday, the Huskies offense showed what they can do when they put their mind to it.

Its coming, its coming: Did Washington finally find the keys to unlocking its offensive firepower? - The Seattle Times

The Flint House, Brighton: Its all about satisfying dishes restaurant review – The Guardian

Posted on October 13, 2019 by Danzig

The Flint House, 13 Hanningtons Lane, Brighton BN1 1GS (01273 916333). All dishes 4-14 (apart from shared steak at 42), desserts 8, wines from 23

Being on trend in the restaurant business isnt difficult, if youve got a few miles on the clock: sniff the air to work out which direction the robata grill smoke is blowing from; flick through a few mags with a grizzled I can do that frown. It doesnt matter that you made your name, say, knocking out a massive raviolo or ripping off the Tatin sisters. Why shouldnt you now do some ersatz take on somewhere called Asia you dont know much about outside of a sweaty mini break at the Park Hyatt Tokyo? If thats what the Swarovski-encrusted iPhone crowd want right now, give it to them. Buy in a few trinkets wholesale from that department store in Nihonbashi, stack the fridge with Cristal and offer up a menu full of miso-smeared cod and dishes that punch you in the face repeatedly with gochujang. Yours for 100 a head.

Being up to date while remaining true to yourself takes more skill. Chef Ben McKellar and his partner Pamela have it. If you havent heard of them, its because you dont live in Brighton, where they have run multiple restaurants for the past 21 years. Their places usually have the word ginger in the title. Its Bens way of celebrating his once luscious head of russet hair.

I first ate his eminently trustworthy food at the Gingerman inside the mildly formal Drakes Hotel in 2005, and then again in 2008 at a laid-back pub called the Ginger Fox just outside Brighton. Back then, there was a touch of St John to his cooking. I still mutter wistfully about his toast fried in duck fat, laid with horseradish cream and pink folds of roast beef. He might put a mince and onion pie on the menu, but raise the humble to the extravagant, or put a cake of crisped pigs head alongside slices of fillet. His dishes have always been on the plate what they promise on the menu.

And now heres the shiny Flint House, in a new development within the citys Lanes. Its seemingly unlike any other McKellar outpost before, which may explain the absence of Ginger in the title. Upstairs is a dining room and cocktail bar looking out over the Brighton rooftops. Downstairs is dominated by a counter around a fully open kitchen for those who like a bit of nerdy cooking theatre. Thrill to the induction hob with its plancha fitting; perv over the Thermomix and the Pacojet, and the prepped ingredients waiting in their plastic pots for their moment.

Its all polished surfaces and sharp angles and yes, of course, small plates because everything is right now. They do not take bookings, because this is meant to be a restlessly modern venture that you fall into and out of at speed. So far so modish. Dont be distracted. Dig through the unstructured menu, its belt unloosened to the last notch. Take in the nods to Spain and Italy. The bit of the menu headed encouragingly Fried/toast/snacks, for example, includes ham croquettes with saffron mayo, which feels like a departure from his overtly British agenda. But youll still find the big fat McKellar thumbprint: its about solid dishes that dont sacrifice substance for looks. The bchamel in those croquettes isnt just flavoured with ham; its spun through with ribbons of the stuff, as if determined to make its point.

Rock oysters are dressed with an apple and cider-vinegar granita, which makes them brisker than they might already be. We watch a hunk of hispi cabbage being seared on the plancha, until the edges are browned and toffee-like. It comes with a thick, mustardy ravigote sauce below and an autumnal leaf fall of crisped golden onions above. Courgettes are browned and pelted with handfuls of pine nuts and a dollop of confit garlic. A slab of treacly bread is toasted and laid with Ortiz anchovies, the brand name a reassurance. There are rings of lightly pickled onion to send it on its way.

As with Ortiz, so with Hannan, the Northern Irish meat producer, who ages his beef in a room lined with the shimmering pink of Himalayan salt. Im still to work out exactly what the salt does, but I know the beef is exceptionally good. Like some terrible brand fetishist, I relax when I see his name on a menu. A serious cut of that beef is the most expensive dish here at 42 (for sharing). Theres also his ox cheek, cured to a rosy red and given a ride through a sugar pit, to produce something on more than nodding terms with the very best maple-syrup-sweetened bacon. Theres a toasty onion pure beneath. It needs the heavy grating of nose-slapping horseradish to tip it away from cloying. And then there are rings of hugely flavoured lambs belly, from an animal with proper time on the hoof, crisped and perched on a pile of the freshest of peas and dressed with more anchovy.

For dessert there is muscovado sugar crme brle. Apparently, there are blackcurrants in there, too, but all I get are the sultry, caramel tones of the brown sugar. I am rarely convinced that there is much point trying to improve upon a classic vanilla crme brle, and this one doesnt change my mind. Far better is a block of chocolate and pistachio parfaits, pushed together and sandwiched within a biscuit shell alongside a cherry cream. Its both fun and clever. Its lunchtime and, to the disgust of many reading this, Im off the booze. Instead I have a glass of their own rhubarb soda, and feel almost virtuous, even though I surrendered my virtue years ago.

My job is to ramble through as much of a menu like this as I can, and I do put my back into it. But sometimes you need to step back from such an experience and work out what its for. Over the years the McKellars have run businesses built around the special occasion; restaurants where milestones are marked and devotion is proved. The Flint House is not one of those. Its about a couple of satisfying dishes, rather than the works. Its a restaurant that makes its point one dish at a time so that what could seem at first to be just a nice enough lunch or dinner, turns out to have been rather more than that. And every town really could do with a place like that.

A little more on McKellars thatched pub the Ginger Fox, just outside Hurstpierpoint, 15 minutes from Brighton. It may be chocolate box-pretty but the food is bang up to date. Starters might include a rabbit scotch egg with carrot and chipotle remoulade, followed by venison loin with braised celery and a wild mushroom jus. Sunday lunches, which come fully accessorised, are a highlight (thegingerfox.com).

Restaurateur Alan Yau, who launched an entire restaurant sector with Wagamama, before opening Hakkasan and Duck & Rice, has three new ventures in London next year. Two will be in Canary Wharf. Chyna will combine Cantonese and European cookery and boast a water market from which customers can choose live seafood. Next to that will be a Japanese place built around counter dining. The third, at Westfield Shopping Centre, will be part of his Turkish street food brand, Yamabahce.

Steve Groves, who won Masterchef: The Professionals a decade ago, has another title. He has been named Craft Guilds National Chef of The Year. Groves, who heads the kitchen at Roux at Parliament Square, won with a menu including red mullet with shellfish mousse and bouillabaisse sauce, and suckling pig with Jerusalem artichokes.

Email Jay at jay.rayner@observer.co.uk or follow him on Twitter @jayrayner1

See the original post here:

The Flint House, Brighton: Its all about satisfying dishes restaurant review - The Guardian

Seahawks at Browns final score, takeaways: Seattle hangs on to beat Cleveland in back-and-forth game – CBS Sports

Posted on October 13, 2019 by Danzig

The Cleveland Browns continue to show they are an undisciplined football team, seemingly incapable of winning games. They were the better team for most of Sunday's game against the Seattle Seahawks but four turnovers and nine penalties secured their demise in a 32-28 loss. The Browns fall to 2-4 entering their bye week. Seattle improves to 5-1.

Baker Mayfield completed 22 of 37 passes for 249 yards, a touchdown and three interceptions.Nick Chubb had 20 carries for 122 yards and two touchdowns. He also had five receptions for 17 yards and a fumble.

Russell Wilson threw his 13th and 14th touchdowns of the season, and he has still yet to throw an interception. Chris Carson continues to build on a strong season recording 124 yards and a touchdown on 24 carries. Seattle does have weaknesses though. The defense did not record a sack. The offense fumbled three times, with two of those being recovered by the defense.

Pete Carroll and his team host the 4-2 Baltimore Ravens next week.

They made fewer errors and they capitalized on Cleveland's. Seattle fumbled three times and was penalized 10 times for 65 yards. The Browns scored zero points off the Seahawks' lone turnover. Meanwhile, Wilson led his squad to 17 points off their opponent's three turnovers and blocked punt.

Wilson does a tremendous job of extending plays while also not putting the ball in harm's way. He has thrown 14 touchdowns this season without a single interception in 176 attempts through sis games. Green Bay Packers quarterback Aaron Rodgers set the record for most consecutive pass attempts (402) without an interception in 2018.

Pick and choose. There were a number of unfortunate occurrences including multiple passes that hit receivers hands only to be intercepted by Seattle. It was the second consecutive week that the Browns threw an interception in the red zone during the waning moments of the first half, and then allowed the opposition to march down the field and score a touchdown. It would be easy to pick any of their nine penalties or the lack of protection on what resulted in a blocked punt by Seattle. It boils down to undisciplined play and that falls on the shoulders of players and coaches alike. The same explanation could be copied and pasted for all but one of their games this season.

For the second consecutive week, it was Cleveland throwing an interception in the red zone before halftime. Baker Mayfield threw a pass behind Jarvis Landry, who tipped it into the hands of Seahawks safety Tedric Thompson. Seattle had time to march down the field and score a touchdown before halftime. It was 20-18 and they were set to get the ball back to start the second half.

The Dawg Pound can hang their hats on this catch by wide receiver Odell Beckham Jr. On a 41-yard pass from Mayfield, Beckham hauled in an improbable sideline catch over safety Tedric Thompson. Well...improbable for everyone else in the league, but we've gotten used to this from OBJ.

During the week, Browns coaches and players said that they need to get the ball to Beckham more. He made six catches for 101 yards but he also dropped a few passes.

There were some controversial calls in this game just as there are in every game. The reason for Cleveland's loss lies more in their lack of execution than officiating, but Mayfield was not afraid to voice his opinion after the game:

"The refs are never an excuse and I'll probably get fined for saying this but it was pretty bad today. The guy was squared up with him, running at him, he was lowering his head into Jarvis. What is he supposed to do? Avoid him? It isn't bull fighting. I don't know. It ticks me off," Mayfield said following the loss.

The 'angry' quarterback was also irritated that officiating missed Seattle grabbing Nick Chubb's facemask on a 4th down stand later in the game.

"Yeah, I was calling it out," he said of his motions at the time. "They didn't see it. It was in the middle of the pile. Another one that we had to overcome."

Seattle's receivers paid homage to legendary boy band N'Sync. Justin Timberlake would have been proud with this celebration following a 17-yard touchdown pass from Russell Wilson to Jaron Brown before halftime. Timberlake is a Packers fan by the way.

Cleveland heads into a much needed bye week. They'll head to Foxboro to take on the New England Patriots though coming off the bye. Seattle gets to face the Baltimore Ravens in Week 7. Lamar Jackson and the Ravens improved to 4-2 this season with a 23-17 win over the Cincinnati Bengals on Sunday, and Jackson put on a record setting show.

If the live blog fails to display, click here to reload.

See the rest here:

Seahawks at Browns final score, takeaways: Seattle hangs on to beat Cleveland in back-and-forth game - CBS Sports

Tom Herman’s tone Monday seemed calculated to make a point to his Longhorns ahead of the Red River Showdown – The Dallas Morning News

Posted on October 13, 2019 by Danzig

AUSTIN -- On a table next to Tom Herman's lectern, one of the phones used by media to record his buttoned-up thoughts suddenly lights up, as does the coach.

"Anyone expecting a call from Fraud Risk?" he asks, then picks up the phone and answers it himself.

"This is Coach Herman."

Except it wasn't.

The jocular fellow at Monday's news conference bore little resemblance to the terse, tightly wound coach who usually leads Texas' weekly news conference. Most Mondays he doesn't have much fun. Only last week, before the West Virginia win, he essentially cut his usual 30-minute availability in half. Given the insight of the answers, no one seemed to mind the quick exit.

Considering that this week at the State Fair, the 11th-ranked Longhorns will play sixth-ranked Oklahoma, a 10-point favorite and purveyor of the nation's most prolific offenseaveraging nearly a first down per play, you'd have thought Herman might retreat further into his shell. Maybe even take the fifth.

On the contrary, his jovial tone Monday seemed calculated to make a point to his team, if no one else:

Lighten up. We got this.

If he wasn't exactly Barry Switzer, at least he tried to be accommodating. When a reporter asked what it's like to play at the Cotton Bowl in October, he repeated a favorite from his days as a graduate assistant at Texas.

Team bus rolls up outside the Midway, where an elderly woman greets the Horns with a two-finger salute. Next to her, a child sweetly follows granny's lead.

"The old double bird," Herman said, smiling. "It crosses a lot of different generations."

He paused after relating the story in front of a bank of cameras, realizing that, in the telling, he might have acted it out a little too well.

"I hope I didn't actually put those up," he said. "That'd be a meme in a heartbeat."

He thought a little more and reminded reporters that the seats ringing the tunnel at the Cotton Bowl's south end belong to Oklahoma fans, who come prepared for the day's events.

"They do a good job of looking up your girlfriend's name and your mom's name and all that stuff," he said.

"There is a lot of not-nice things said."

Of course, the trash talk runs both ways. It's not Sunday school. The idea is to get in the head of a blood rival any way possible.

The mind games didn't start this week, either. Last week against West Virginia, for instance, the Longhorns unveiled a trick play with nine minutes left and Texas up by 11 at the Mountaineers' 12. Samuel Cosmi, a 6-7, 300-pound offensive tackle, caught a long lateral from Sam Ehlinger, then used all 10 gears to cover the 12 yards in question.

Now, you might ask, as an Austin columnist did, why not save such an unexpected play for Oklahoma?

Why pile up points in Morgantown while tipping your hand to the Sooners in the process?

"We don't like kicking field goals in the red zone," Herman said. "So we are going to pull out all the stops to score touchdowns down there."

What he didn't say: Now Oklahoma has to spend time in practice this week preparing for another Samuel Cosmi rumble, just in case.

What all parties should expect otherwise is another barn burner. Might not end like last year, when the Longhorns held off a wild comeback led by Kyler Murray. But, as Herman said Monday, it ain't going to be 10-7, either.

And as the points mount, emotions invariably rise with them. A young secondary depleted by injuries needs to understand as much going in. On its best day, the Texas defense won't stop an offense conceived by Lincoln Riley and executed by Jalen Hurts.

Herman's job this week will be to persuade his kids that no matter what happens or how many points the Sooners ring up in a setting unlike any other in college football, they can't lose their heads. In order to accomplish such a mission, it's better to be loose than uptight.

So Herman will remind his players that they're 10-point underdogs. He'll tell them that no one expects them to win, even though their only loss is to a team far better than anyone Oklahoma has faced. Chances are, it might even play.

Never mind that if Texas loses Saturday, any lingering CFP hopes are buried. The committee wouldn't take a two-loss Texas team, no matter what it does in the Big 12 title game.

Naturally, that wasn't the message Monday, subliminal or otherwise. Even on his way out the door, Herman stuck to his theme.

"Somebody better call Fraud back, by the way."

No, he's no Mike Leach. Props for trying, though.

Go here to see the original:

Tom Herman's tone Monday seemed calculated to make a point to his Longhorns ahead of the Red River Showdown - The Dallas Morning News

The UK Knew Its Passport AI Was Racist and Used It Anyway – Futurism

Posted on October 13, 2019 by Danzig

Sufficient

The U.K. government uses facial recognition AI to check travelers photos when they apply for passports. It works just fine for white people, but like so many algorithms out there, it doesnt work well when presented with dark skin.

Anti-black bias in tech is nothing new, unfortunately: algorithms trained on biased data have often resulted in software that perpetuates prejudice. Whats particularly troubling about this passport photo AI is that the British government knew about the problem, according to New Scientist but decided it was okay to deploy the system anyway.

Newly-released internal documents revealed that the same racial disparities occurred during testing, resulting in the system telling darker-skinned people that their pictures didnt comply with passport guidelines, New Scientist reports.

User research was carried out with a wide range of ethnic groups and did identify that people with very light or very dark skin found it difficult to provide an acceptable passport photograph, read the documents. However; the overall performance was judged sufficient to deploy.

If someone applying for a passport is told that their photo isnt acceptable, they can still circumvent the AI system and submit it anyway buttheyll face warnings that it could interfere with their application.

Even with the user being able to override the selection, it is still creating a largely racialized disparity in experience between users, University of Washington engineer Os Keyes told New Scientist.

READ MORE: UK launched passport photo checker it knew would fail with dark skin [New Scientist]

More on facial recognition: Google Contractors Tricked Homeless Black People Into Face Scans

Read the original here:

The UK Knew Its Passport AI Was Racist and Used It Anyway - Futurism

Watching This Volcano Erupt From Space Is Absolutely Epic – Futurism

Posted on October 13, 2019 by Danzig

Big Smoke

Watching a massive volcano erupt is truly jaw dropping but thats nothing compared to the incredible view astronauts get from the International Space Station.

NASA astronauts were treated to an amazing sight this past summer, according to Syfy Wire, when the Raikoke Volcano on the Kamchatka Peninsula in Eastern Russia erupted into a massive cloud of dark smoke. Ash and volcanic gases created a giant plume above the 2,300 foot diameter crater as the International Space Station cruised by overhead.

The image above shows convection currents causing a vertical plume to rise above the volcano.

There are about 300 volcanoes in the surrounding areas according to NASA, roughly 29 of them active. The reason why there are so many is because the peninsula lies on top of a tectonic ridge where the Pacific plate is being pushed underneath the North American plate.

A second image shows the particlesgetting washed out across the peninsula by the wind.

Plumes that reach the stratosphere, around the altitude of cruising commercial airliners, stick around much longer than the plumes below, having a much greater effects on both aviation and climate, as NASA points out.

READ MORE: A volcano blows its top, seen from space [Syfy Wire]

More on volcanoes: Humans Produce 100x More CO2 Than All Volcanoes Combined

See the original post:

Watching This Volcano Erupt From Space Is Absolutely Epic - Futurism

Select Page ::